NASDAQ NMS - GLOBAL MARKET · GNLX
0.00% · $0.0000 · Vol Not reported
Market closed · last close shown
Genelux Corp

Genelux Corp

Biotechnology
$2.52
Card
Relationship Map

Follow $GNLX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $GNLX by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
GNLX
Genelux Corp
Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

38/ 100
Veridion Score
Lower range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Wed Oct 7 · last completed session · Pre-market · regular session opens 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is GNLX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading GNLX catalysts
About Genelux Corp
PHARMACEUTICAL PREPARATIONS
Listed since
2023
Employees
26
Country
US

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$2.52
Last session
Day high
$2.52
Last session
Day low
$2.52
Last session
Previous close
$2.52
52W high
$8.24
-69.42% from high
52W low
$2.30
4% of range
Market cap
$114M
EPS
$-0.8200
Beta
1.33
Shares out
45.2M
Avg volume
276.8K
VWAP
$2.52
Last session
Price history computed in-house
1W
0.00%
1M
-0.79%
3M
-16.83%
1Y
-46.95%
YTD
-42.20%
SMA 50 $2.62 · below
SMA 200 $2.82 · below
52W position 4%

GNLX overview

Veridion Score
38
Registered · 2026-10-07
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around GNLX.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading GNLX Form 4 filings
Public disclosures

Congress activity in GNLX

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

GNLX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for GNLX in this window.
Lobbying spend

GNLX lobbying filings, year to date.

Registered lobbying filings matched to Genelux Corp.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for GNLX in this window.
Loading news for GNLX
Analyst ratings
Sovereign unlock shows live analyst consensus for GNLX.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.